Severes epsis is al ife-threatening condition that may occur as as equela of intra-abdominalinfections (iais) of all types. diagnosis of iais is predicated upon the combinationofphysical examination and imaging techniques. diffuse peritonitis usually requires urgent surgicalintervention. in the absence of diffuse peritonitis, abdominal computed tomography remains the most useful test for the diagnosis of iais, and is essential to both guide therapeutic interventions and evaluate suspectedt reatmentf ailure in the critically ill patient. parameters most consistently associated with poor outcomes in patients with iais include increased illness severity,f ailed sourcec ontrol, inadequate empiric antimicrobial therapy,a nd healthcare-acquired, as opposed to community-acquired infection. Whereasc ommunity-acquired iai is characterized predominantly by entericg ram-negative bacilli and anaerobest hata re susceptiblet on arrow-spectrum agents, healthcare-acquired iai (e.g. ,anastomotic dehiscence, postoperativeorgan-space surgicals ite infection) frequently involves at least one multi-drug resistant pathogen, necessitatingbroad-spectrum therapyguided by both culture results and local antibiograms. the cornerstoneofeffective treatmentfor abdominal sepsis is early and adequate source control, which is supplemented by antibiotic therapy,restoration of afunctional gastrointestinal tract (if possible), and support of organ dysfunction. furthermore, mitigation of deranged immune and coagulation responses via therapyw ith recombinant human activated protein Cm ay improve survival significantly in severe cases complicated by septic shock and multipleorgan dysfunction syndrome.
Intra-abdominal infections (IAIs) represent adiverse group of diseases that areencountered commonly in surgical practice. Most IAIs may be controlled effectively and with low associated morbidity through removal or repair of the infected focus, treatment with narrow-spectrum pathogen-specific antimicrobial therapy (if indicated), and restoration of anatomy if resection is performed for definitive source control. However,i nc ertain instances, overwhelming infection leads to excessive activation of the immune response, generalized inflammation, hemodynamic instability, multiple organ dysfunction syndrome (MODS), and eventual death. In such cases of severe sepsis or septic shock secondary to IAI, termed abdominal sepsis, mortality is approximately 25-35% (1, 2), but may exceed 70% (3, 4). Treatment of abdominal sepsis is predicatedupon adequate physical drainageo rr esection of the infected focus, termed source control, which may range from percutaneous drainage to serial laparotomies and open abdominal wound management in severe cases (5).H owever, both judiciousa ntimicrobial therapy and effective support of organ dysfunction also impact upon survival. This review will highlight the symbiotic disciplines of surgery,infectious diseases, and critical care in the management of abdominal sepsis.
DEfINITIONS
Guidelines put forth recently by the International Sepsis forum Consensus Conference form the basis for the current definitions of IAIs, as well as the five additional most common infections in patientsw ith sepsis (pneumonia, blood stream infection, urosepsis, surgical site infection [SSI] , and catheter-related infection) (6). In the most general sense,IAI is defined as infection of any intra-abdominal viscus, with or (rarely) without involvement of the overlying peritoneum. Infections of the gastrointestinal(GI) tract aredichotomized traditionally and for clinical research purposes into uncomplicated and complicated types ( fig. 1) (7) . In the former,infection is contained within asingle organ, such that thereisnoanatomic disruption of the GI tract. In the majority of uncomplicated IAIs, definitive management is surgical, and antibiotics arenot warrantedbeyond prophylaxis of the incision against SSI. Uncomplicated IAIs almost never cause critical illness and aren ot considered further herein, although ac omplicating nosocomial infection could make matters worse (8).
By contrast, complicated IAIs extend beyond the source organ and into the peritoneal cavity through aperforated viscus, thereby stimulating the systemic inflammatory response to ag reater degree. The extent of infection dependsupon containment by local intra-peritoneal host defenses,a lthough dissemination of pathogensisfacilitated in general by the presence of peritoneal fluid and repetitive motion of the diaphragm. Contained infection results in the formation of an intra-abdominala bscess, with minimal or no inflammation of the overlying peritoneum. Abscess formation is facilitated by foreign bodies (to lower the inoculum size) and microbial synergy,and createsalow pH environment that impairs phagocyte function and impedes permeation of both immune cells and antibiotics. Uncontained spread of infection leads to diffuse peritonitis, acondition characterized by higher mortality,a nd necessitating urgent celiotomy (9).
Peritonitis is defined according to both its cause and extent. In primary peritonitis, the source of infection does not arise from the GI tract, and thereisno identifiable anatomical derangement of the intra-abdominal viscera. By contrast,secondary peritonitis is due to infection of the abdominalv iscera, and may arise as aconsequence of perforation, ischemic necrosis, or penetratingi njury.T ertiary peritonitis is defined as peritonitis that persists after moret han one failed source control procedure( 9). Management of tertiary peritonitis presents a particular challenge due to the increased likelihood of infection with multidrug-resistant (MDR)organisms such as enterococci, Pseudomonas aeruginosa,a nd Candida spp. (fig. 2 ), as well as the frequent need for re-laparotomyinhemodynamically tenuouspatients. Whether tertiary peritonitis represents invasive infection or colonization in the setting of complete failureo fa bdominal host defenses is controversial,asisthe use of open-abdomen management techniques to promote mechanical peritoneal toilet (discussed below). fortunately,t he incidence of tertiary peritonitis is decreasing (10). One final distinction of crucial importance involves differentiation of community-acquired (CA-) from healthcare-acquired IAI (HA-IAI). The former is characterized in general by microorganisms that are sensitive to narrow-spectrum antimicrobial agents.C onversely,H A-IAIs develop in hospitalized patients, residents of long-term carefacilities, or patients who have been treated recently with antibiotics. All postoperative IAIs arec onsidered HA-IAIs. Although HA-IAIs arefar less common than CA-IAIs, they are associated with markedly increased mortality due to both underlying patient health status and increased likelihood of infection caused by MDR organisms (11).
Intra-abdominal infection
Although most IAIs result in activation of the inflammatory cascade to some degree, strict criteria exist for the documentation of the systemic inflammatory response syndrome (SIRS). The diagnosis of SIRS involves fulfillment of two or moreo ft he following criteria: (1) Coreb ody temperature>38°Co r<36°C , (2) heart rate >90beats per minute, (3) respiratory rate >20breaths per minute (not ventilated) or P a CO 2 <32m mH g( ventilated), (4) WBC >12,000, <4,000 or >10% immatureforms (bands) (12). When SIRS is due to infection, it is termed sepsis. In turn, sepsis due to IAI is termed abdominal sepsis. Sepsis with acute dysfunctiono fa tl easto ne organ is termed severes epsis, whereas septic shock is severes epsis with hemodynamic instability refractory to fluid administration, with arequirement for vasopressor support.
EPIDEMIOlOGY
Outcomes following IAIs areinfluenced by the origin of the infection, the abilityofthe host to contain the infection, the degree of physiologic derangement due to the infection, and both the rapidity and adequacy with which the infection is treated (Table 1) . Accordingly,the overall mortality rate associated with IAIs varies markedly and ranges from <1%t o>70%, although most modern case series of secondary peritonitis with severesepsis or septic shock have reported an average mortality of approximately 30% (2-4, 9, 11,13-20) .
The most common source of infection in CA-IAIs is the appendix, followed by the colon, and then the stomach (11, 20, 21). Among patients with HA-IAIs, the predominant etiology is enteric anastomotic disruption. Dehiscencec omplicates 5-10% of intra-abdominal intestinal anastomoses, and is associated with an increased likelihood of mortality (22-24). Several risk factors for intestinal anastomotic dehiscence arerecognized and fall broadly into the categories of underlying health status, operative technique, and postoperative management ( Table 2 ). In both postoperative and non-postoperative HA-IAIs,t he most common source of infection is thec olon,f ollowed by the stomach, pancreas, small intestine, and appendix (21, 25). Peritonitis originating from the pancreas portends as ubstantially higher mortality, and from the appendix lower,a sc ompared to other abdominal viscera (11). Mortality from HA-IAI is greater than from CA-IAI (11, 26, 27). Healthcare-associated, non-postoperative IAIs, which arise in patientshospitalizedfor reasons unrelated to abdominal pathology,portend aparticularly poor prognosis (21, 28). In such cases, diagnosis is often delayed due to both alow index of suspicion, poorunderlying health status, andaltered sensorium. Healthcare-associated IAIs, both postoperative and non-postoperative, ares ignificantly more likely to involve pathogens that arer esistant to narrow-spectrum agents (9, 21, 25, 29) ( fig. 3 ). furthermore, patients with HA-IAIs aremorelikely to be treated in-adequately as compared to patients with CA-IAIs, contributing to increased treatment failures, morbidity,and mortality (29).
As many as 40% of patients with peritonitis may progress to abdominal sepsis (30, 31). Sepsis, regardless of its source, is al eading cause of mortality worldwide. Using recentdata from the United States, the rate of severes epsis was estimated to be three cases per 1,000 population, for atotal of 751,000 cases annually (32). further extrapolation of this data internationally reveals aglobal incidence of 18 million cases annually,m aking sepsis al eading cause of death worldwide (33). Of these cases, approximately 20% aresurgical, and one-half of surgical cases result from an abdominal source of infection. Abdominal sepsis, as compared to other sources, is associated with increased mortality (1, 34). Both abdominal sepsis, andsepsis in general, impose astronomical financial burdens upon the health caresystem (35).
MICROBIOlOGY
The commensal flora of the GI tract varies by location; whereas the oropharynx contains predominantly anaerobes and streptococci, both the stomach and duodenum aretypically sterile.The remainder of the GI tract ( i.e.,distal small bowel, colon, and rectum) is characterizedp redominantlyb ye nteric aerobic or facultative gram-negative bacilli (GNB) (also known as Enterobacteriaceae or coliforms) and anaerobic GNB, which increase in percentage from the proximal jejunum to the colon, wheret hey predominate. Pathogens isolated from cases of infected pancreatic necrosis also resemble closely the flora of the large bowel (36), as it is postulated that the pathogens may invade the retroperitoneum via bacterialt ranslocation from the gut. The vast majorityo fI AIs arep olymicrobial and most commonly involve enteric GNB (Table 3 ) (37, 38). In vitro susceptibilityofGNB isolated from IAIs arecatalogued annually by the Study for Monitoring Antimicrobial Resistance Trends (SMART), which is an international surveillance program to monitor resistance patterns globally (39) . The SMART report for 2004, the most recent year for which complete data area vailable, involved 81 medical centers from 28 countries for atotal of 6,156 GNB from 5,731 patients. EntericG NB comprised 86% of isolates, including Escherichia coli (48.4%), Klebsiella spp. (16%), and En-terobacter spp. (9%). Althoughthe prevalenceofMDR organisms such as P. aeruginosa and Acinetobacter baumannii remained unchanged, antimicrobial resistance, particularly to fluoroquinolones and β -lactam agents, is increasing on an international scale. furthermore, MDR GNB have now been isolated from cases of CA-IAI in parts of South America and Asia. These ominous results underscoreboth the discretion that must be employed when prescribing empiric antimicrobial therapy and the need for novel agents for the treatment of IAIs (40).
Anaerobic bacteria, such as Bacteroides spp. and Clostridium spp., arei solated in approximately 10% of IAIs and clearly play ar ole in infection (41-43). The prevalence of these bacteria is almost certainly underestimated due to both poor specimen collection technique ( e.g.,exposuretoatmospheric oxygen) and the difficultly with which they are cultured. Although anaerobic bacteria aref ound predominantly in the distal small bowel and colon, they may be isolated from both the stomach and proximal small bowel in cases of distal obstruction.
finally,g ram-positive bacteria, such as staphylyococci and enterococci, areisolated in approximately 10-20% of IAIs, with an increased prevalence in cases of HA-IAI (25, 44) ( fig. 3 ). The role of enterococci in IAIs, and thus the need to provide empiric coverage againstt hem, remains unclear( discussed below).
Althoughthe peritoneal fluid of as many as 20% of patients with acute perforation of the GI tract may ultimately grow Candida spp., IAIs caused by fungi arerareinthe immunocompetent host (45). However, when they do occur,they aremorecommonly implicated following upperGIsources of infection, as well as with infected pancreatic necrosis (19, 46). furthermore, isolation of Candida spp. in patients with HA-IAIs is associated independently with mortality (21, 47, 48). In one recent series of critically ill patients with Candida peritonitis,m ortality exceeded 50% (48).
Secondary peritonitis is accompanied by bacteremia of the same microorganism in as many as onefourtho fc ases (21), and coexisting bacteremia is associated with increased mortality (21, 29). Accordingly,o rganisms isolated from both peritoneal fluid and blood should always be treated. furthermore, subsequent nosocomial infections (most commonly urinaryt ract and surgical site infections) occur frequently in patients with IAIs and areassociated with an increased likelihood of MDR infection, as well as increased morbidity and mortality (8).
DIAGNOSIS
Intra-abdominal infection in the awake patient is suspected in the presence of SIRS as well as abdominal pain and tenderness. Abdominal rigidity,g uarding (either voluntary or involuntary), and rebound tenderness suggest peritonitis and the need for urgent laparotomy.Both local and diffuse inflammation may result in paralytic ileus with resultantabdominal distention, obstipation, and vomiting. Oliguria,h ypo- tension, and altered mental status may ensue in cases of septic shock. With obtundedorcomatose patients, many symptoms may be either attenuated or absent, rendering diagnosis difficult, and necessitating ahigh index of suspicion. Indirect evidence of infection, such as unexplained acidosis, new organ dysfunction (49), inability to tolerate enteral feeding, or unexplained fluid requirement, should prompt adiagnostic work up for IAI, especially in the setting of recentabdominal surgery.
Physical examination findings suggestive of IAI are confirmed by abdominalimaging,accomplished most commonly by computed tomography (CT)with both enteral and intravenous contrast. Due to extremely favorable performance characteristics,abdominal CT is the diagnostic test of first choice for all patients with suspected intra-abdominal pathology with few exceptions ( i.e., suspecteda cute appendicitis in a healthy young male patient) (50, 51). Abdominal CT may provide awealth of detailed information and is useful to confirm the diagnosis of IAI, implicate the responsible pathologic process (e.g.,p erforated sigmoid diverticulitis with adjacent abscess),and guide the method of drainage (i.e, percutaneous vs. surgical) based on the anatomic landscape.
Microbiologic diagnosis of CA-IAIs is of no value in initial treatment because culturer esults aren ot available at the time that empiric antibiotic therapy is initiated. furthermore, because the vast majority of pathogens responsible for CA-IAIs aresusceptible to narrow-spectrum agents, routine obtainment of cultures is unnecessarya nd has been shown to not influence outcomes (52). Conversely,m icrobiological analysis of HA-IAIs is mandatory due to different microbiology and the marked variability of resistance patternsobserved amongthe isolates (53) . Data from such cultures, once available, will dictatethe need to modify broad-spectrum empiric therapy.
TREATMENT fundamentalprinciples involved in the treatment of abdominal sepsis include source control, restoration of GI tract function, systemica ntimicrobial therapy, and support of organ function. Minimization of the intervals from presentation to diagnosis and diagnosis to initiation of therapyimpacts significantly upon survival (54). However,aggressiveinterventions such as re-laparotomy and empiric broad-spectrumantibiotic therapy must be considered with caution in light of the potential for tissue injury or substantial toxicity,respectively.
SOURCE CONTROl
Source control is defined as any and all physical means necessarytoeradicate afocus or infection, as well as modify factors that maintain infection, such as leaking intestinal contents. Inadequate source control at the time of the initial operation has been associated consistently with increased mortality in patients with IAIs,despiteboth adequate antimicrobial therapy and organ support(13, 55). Accordingly,barring hemodynamic instability,every effort should be made to achieve source control as soon as possible after the diagnosis of IAI has been made.
Methods of source control fall broadly into either percutaneous or operative interventions. The choice of technique is dependent upon patient acuity,a natomic site, and extent of infection. In general, the procedurethat achieves source control with the least associated morbidity is preferred.
laparotomy remains the cornerstone of carefor all cases of diffuse peritonitis. One randomizedt rial compared celiotomy to limited surgical drainageo f IAIs via an extraperitoneal approach in the absence of peritonitis (56), finding that morbidity was reduced substantially by the morel imited approach, but percutaneous drainage techniques have been developed subsequently.S ince then, results from several retrospective studiess uggest that isolated IAIs that area natomically amenable to percutaneous drainagemay be treated with safety (57-59). The percutaneous approach is generally contraindicated whenadequate drainage is not possible (i.e., multiple small abscesses) or anatomically not feasible (i.e., overlying bowel), and when repair of anatomic structures is necessary.A lthough laparoscopic drainage of IAIs has been reported, this technique has not been compared directly to either percutaneous or open drainage (60).
In cases of abdominal sepsis, as ingle operation may not be sufficient to achieve source control, thus necessitating re-exploration. The decision to perform an additional laparotomy is often challenging to make in the face of an unstable patient in which symptoms of reinfection areo ften either subtle or absent. Koperna et al. reported that increased age, hypoalbuminemia, thrombocytopenia, increased preoperative Acute Physiology and Chronic Health Evaluation (APACHE) II score, and preoperative organ failurep redicted the need for re-laparotomy among ac ohort of patientsw ith secondary peritonitis (61). Mortality was increased significantly in those patients who required reoperation as compared to those who did not (51% vs. 4%, p<0.0001).
Three methods of local mechanical management of abdominal sepsis following initial laparotomy for source control arecurrently debated: (1) Open-abdomen (also known as laparostomy),( 2) planned relaparotomy (PR), and (3) on-demand re-laparotomy (ODR). Open-abdomen management involves temporary coverageofthe abdominal contents with polyglactin mesh, towels,abdominal "zipper,"orvacuumassisted closure( 4, 26, 62). In certain instances, this technique is mandated either to avoid abdominal compartment syndrome or because of physical inability to re-approximate the abdominal fascia regardless of intra-abdominalpressure. However,some experts have also advocated elective open-abdomen management for cases of abdominal sepsis in which source control is unclear or known to be inadequate (63). Purported benefitsofanopen abdomen include reduction in intra-abdominalp ressure, morec omplete drainage of infection, early detection of additionalanastomotic leaks or new abscesses, facilitation of reoperation (including serial laparotomies at the ICU bedside), and minimization of additional abdominal wall trauma. However,t hese benefits may be negated by the increased morbidity caused by fluid and protein loss, fistula formation, and ventral herniation (15, 64).
Planned re-laparotomy involves the ap riori decision to re-explorethe abdomen regardless of clinical circumstance. By contrast, ODR is performed only in the case of subsequent reinfection, usually indicated by either clinical deterioration or failuret oi mprove despiteboth presumed source control and appropriate antimicrobial therapy.P lanned re-laparotomy is indicated if adequate source control is clearly not obtained at the time of the initial operation. In all cases, the benefits of moreeffective source control must be weighed againstthe potential morbidityofbleeding, damage to edematousviscera or the abdominal wall (65), and stimulation of additional inflammation (66).
These three techniques (ODR, PR, open abdomen) have not been compared in ar andomized fashion, and the observational literaturei sl imited markedly by subjective managementdecisions made by the surgeon at the time of the initial laparotomy.This decision, in turn, is dependent on multiple clinical factors that determine patient outcome independent of man-agement strategy,most notably the severity of illness. Methodologicall imitations notwithstanding, observational comparisons of the open abdomen and relaparotomy (either PR or ODR) techniques have not demonstrated as ignificant advantage to either (15, 67). furthermore, several studies, using am atched case-control design, have failed to show ab enefit to the PR as compared to the ODR approach after adjusting for severity of illness (18, 61, 68-70). These findings werec onfirmed in ar ecent meta-analysis that, despite significant heterogeneity among studies, didnot report asurvival advantage to the PR as compared to the ODR approach [pooled odds ratio (OR) =0.70, 95% CI [0.27, 1.80], p=0.50] ( fig. 4 ) (71). Multi-institutional randomized controlled trials (RCTs), which theoretically eliminate confounding due to underlying clinical status or variations in patient management, areneeded beforeany meaningful recommendationscan be made. finally,u ndirected or "blind" re-laparotomy prompted by unexplained MODS in the absence of supporting clinical or radiographic data is associated with an unacceptably high rate of negative re-laparotomy (72-74). Highly specific imaging with abdominal CT has all but obviated the role for such aprocedure. Rather,c linical deterioration in the absence of radiographic findings and assuming adequate antibi-Individual and pooled odds ratios (ORs)(planned versus on-demand re-laparotomy) for the eight studies included. Pooling was according to the random-effects model. Squares and bars indicate study size and confidence interval, respectively. Elongated diamond represents the confidence interval of [0.27, 1.80]. Test for heterogeneityofthe eight studies: χ 2 =40.7, df =7,p<0.001; test for overall effect: p=0.50. Reproduced with permission from (71). fig. 4 . Results from meta-analysis of planned vs. on-demand re-laparotomy strategies for secondary peritonitis. otic therapy should prompt as earch for another source of infection (8).
Ample evidence suggests that source control should be obtained as early as possibleafter the diagnosis of IAI has been confirmed. Delayed intervention significantly decreases the ability to achieve source control, with an associated increase in mortality (18). One notable exception concerns infected pancreatic necrosis, during which delayed surgery may result in decreased mortality due to an increased opportunity for demarcation of viabletissue planes, allowing limited debridement and reduced surgical blood loss (75, 76).
RESTORATION Of fUNCTION
following removal of infected tissue, attention should shift to the restoration of anatomy and functionality of theG It ract. Staging of procedures intended to restoreintestinal continuity continues to be amatter of debate, particularly with respect to IAI caused by colonic perforations. The past two decades have witnessed ashift from the traditional three-stage proceduret ot he two-stage Hartmann procedure, with a decrease of associatedm ortality (77). Most recently, several reports have touted the safety of aone-stage proceduref or colonic perforation with associated peritonitis, involving abscess drainage, resection,and primary anastomosis (78-80). However,t hese nonrandomized trials involved patients with sepsis infrequently,and the extent of surgery should be dictated primarily by the degree of physiologic derangement, given the strong relationship between severity of illness and treatment failure. In the presence of hemodynamic instability,r e-establishment of intestinal continuity of any kind may be prohibitive, necessitating re-laparotomy within the next 24-48 hours.
ANTIMICROBIAlTHERAPY
Antibiotics area dministered to prevent both local and hematogenous spread of infection, as well as to decrease delayed complications. Provided adequate source control has been obtained, outcomes in HA-IAI arei nfluenced heavily by the administration of adequate initial antimicrobial therapy,d efined as at least one agent to which the offending pathogen is sensitive, in the correct dose, and in atimely manner (20, 29, 53, 81, 82). furthermore, the increased mortality associated with inappropriate empiric antibiotic therapy cannot be reversed by subsequent modifications (20). Accordingly,knowledge of patient risk factors for infection with MDR pathogens ( Table 4) , as well as localr esistance patterns, is essential. Stratification by risk ensures that all patients will receive therapy that is activea gainst the offending pathogens, and minimizes superfluous use of broad-spectrum agents, which increases costs,exposes patients to potential drug toxicity,a nd exerts selection pressuref avoring the emergence of MDR organisms (83).
Evidence-based guidelines regarding the selection of antimicrobial therapyf or IAIs have been formulated by the Surgical Infection Society,the Infectious Diseases Society of America, the American Society for Microbiology,a nd the Society of Infectious Disease Pharmacists (84, 85). In the case of uncomplicated IAIs, the focus of infection is treated effectively by surgical excision of the involvedtissue alone, and the administration of antibiotics is unnecessary beyond preoperative prophylaxis. Additional cases in which IAI is not considered established, and thus extended antimicrobial therapy is not warranted, ares ummarized in Table 5 .
Recommendedsingle and multi-drugregimens for the treatment of IAIs areshown in Table 6 . In general, empiric regimens should provide coverage against Generalization as to effective treatment regimens against such infections remains challenging due to substantialvariability in both indigenous pathogens and resistance patterns among ICUs. furthermore, antibiotic trials of patients with IAIs typically limit enrollment of critically ill patients or exclude them altogether (86, 87). Treatment options for HA-IAIs include extended-range β -lactam/β -lactamase agents such as piperacillin/tazobactam, carbapenems such as imipenem-cilastatin or meropenem, or at hird-or fourth-generation cephalosporin plus metronidazole. In general, fluoroquinolones should be used judiciously based on resistance emerging internationally (39). furthermore, recent data indicate that aminoglycosides possess inferior efficacy as compared to agents with comparable activity for the treatment of IAIs, albeit with conventional (i.e., not once-daily) dosing (88). Potential ototoxicity and nephrotoxicity represent additional disincentives to selecting aminoglycosides as first-line therapy.Combination therapy directed against as pecific pathogen ( e.g. ," doublecoverage" of Pseudomonas)isunlikely to provide benefit in sepsis generally,a nd may worsen outcomes (89).
Newer agents that have demonstrated non-inferiority when compared to standardb road-spectrum regimens for the treatment of patients with IAIs include tigecycline (90), ertapenem (82), and moxifloxacin (91). Among these drugs, ertapenem is particularly appealing because of once-dailyd osing and possible decreased induction of MDR GNB (92). However,w hether these drugs should be used empirically for HA-IAI is unknown, particularly because the anti-pseudomonal activities of tigecycline and ertapenem, in particular,are unreliable.
The optimal duration of antimicrobial therapy is unknown. Current recommendations advise continued therapyu ntil clinical signs of infection have resolved, includingfever and abdominal pain, normalization of the WBC count, and restoration of GI function. Providedthese criteria aremet, the likelihood of re-infection after discontinuation of antibiotic therapy of CA-IAI is exceedinglysmall (93, 94).T ypically,this will involve between 5-7days of therapy,although shorter courses have been proposed(95). In the presence of clinical improvement and af unctional GI tract, antibiotics may be transitioned safelyfromthe intravenous to the oral route (96). The optimal duration of therapy of HA-IAIi su nknown and urgently in need of study (97).
Persistent sepsis after one week of antibiotic therapy should raise the possibility of inadequate source control, tertiary peritonitis, or anothern osocomial infection (e.g., ventilator-associated pneumonia). In suchcases, arenewed diagnostic evaluation is preferable to either prolongation of the current antibiotic regimen or wholesale change to am oreb road-spectrum empiricregimen, as persistent abdominal symptoms areu sually the result of an ongoings ource of infection that may be amenable to surgical treatment (98).
Althoughe nterococci arei solated in as many as 25% of IAIs (2, 99), they area lmost always found in the setting of polymicrobial infection. Isolation of enterococci from IAIs is associated with HA-IAIasopposed to CA-IAI, increasing age, moreseveredisease, co-isolation of MDR pathogens such as P. aeruginosa, and increased mortality (19, 44). However, the therapeutic implications of the association between enterococci and adverse outcomes in patientsw ith IAIs remain unclear (100) . Several RCTshave shown that treatmentofsuch infections with antibiotic regimens that lack enterococcal activity does not resultintreatment failured ue to enterococcal infection (2, 25, 43, 101-107). Consequently,r outine coverage of enterococci in cases of CA-IAI is not recommended (84, 85, 100). Conversely, most authoritiesmaintain that empiric coverage of enterococcishould be considered in certain clinical circumstances, includinga bdominal sepsis due to HA-IAI (Table 7) .
Similarly, systemica ntifungal therapy for treatment of Candida spp. isolated from IAIs is unnecessary in theabsenceofimmunosuppression. However, isolation of fungi from two or morenormally-sterile sites ( e.g. ,p eritoneal cavitya nd lower respiratory tract) of critically ill patients shouldp rompt consideration of empiric antifungal therapy,typically with intravenous fluconazole. In cases of fluconazole-resistant Candida spp., eithera ne chinocandino rv oriconazole may be considered in lieu of amphotericin Bd ue to the substantial systemic toxicity associated with the latter.
RECOMBINANT HUMANACTIvATED PROTEIN C Drotrecoginalfa (activated) [recombinant humanactivated protein C( rhAPC)] gaineda pproval worldwide for the treatment of severes epsis associated with ahigh risk of death in 2001 following apivotal RCT that demonstrated ar elative risk reduction for mortality of 19% for patients treated with rhAPC as compared to placebo (108) . Initial concern was raised for the use of APC specifically in surgical patients because of an attenuated absolute risk reduction for mortality compared to the overall sample (3.2% vs. 6.0%, respectively), as well as an increased risk of bleeding. In response to this criticism, as urgical evaluation committee adjudicated the results of the original trial for surgical patients( n=474/1,690, 28.0%), and specifically for those surgical patients with severesepsis of abdominal origin (n =295/474, 63.0%) (55). Among those patients undergoing abdominal procedures, the absoluterisk reduction was 9.1%, and the relative risk of 28-day mortality was 0.70 (95% CI 0.48-1.03). In as ubgroup of these patients with an APACHE II score≥25 points, the absolute risk reduction was 18.2%. furthermore, the rates of serious bleeding events among patients who received rhAPC did not differ between the surgical and non-surgical cohorts( fig. 5 ). Amorerecent analysis of the INDEPTH database, which currently contains five clinical trials of the efficacy of rhAPC, demonstrated as ignificant risk reduction for mortality (adjusted OR =0.66, 95% CI (0.45,0.97)) for rhAPC as compared to placeboa mong high-risk (APACHE II score≥25 points) surgical patients, over one-half of whom had had IAIs (109) . finally,ar ecent analysis using amatched cohort design of patients with septic shock of abdominal origin from our institution revealed amorethan 5-fold increase in the likelihood of mortality in controls as compared to patients who received rhAPC (1). Therapy with rhAPC should be considered for patients with severeabdominal sepsis associated with ah igh risk of death, defined as an APACHE II score≥25 or dysfunction of at least two organs.
CONClUSIONS
Although both acuity and underlying health status impact the likelihood that IAIs will progress to abdominal sepsis, as ubstantial body of evidence suggests that the outcomes from this disease ared etermined primarily by the rapidity with which source control is achieveda nd the extent to which the infected focus is cleared. Antibiotic therapy is secondary to adequate source control and ineffective in its absence. furthermore, antibiotics must be administered with respect to the likelihood that HA-IAI is due to MDR pathogens. Selection of the optimal method for both source control and restoration of GI tract anatomyi nvolves ar isk-benefit analysis concerning patient stability,e xtent of infection,a nd associated morbidity.Emerging therapies (e.g.,rhAPC) directed at modulation of the coagulation and immune responses have provided effectivea djuncts to the treatment of abdominalsepsis. Collective implementation of these principles affords the critically ill patient with IAI the greatest chance for survival. 
